Bioavailability of BIBR 953 ZW in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Boehringer Ingelheim
Related studies linked through entity extraction aliases.
Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects
- Status
- COMPLETED
- Phase
- PHASE1
BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Relative Bioavailability of Single Doses of Dabigatran Etexilate When Administered Alone or in Combination With a Single Dose of Ketoconazole or in Combination With q.d. Ketoconazole at Steady State in Healthy Male and Female Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Bioavailability of BIBR 1048 MS With and Without Pantoprazole Under Influence of Food in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Bioavailability of BIBR 953 ZW Under Influence of Food in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Tolerability of BIBR 953 ZW IV and Bioavailability of BIBR 1048 Tablet and Solution in Healthy Males
- Status
- COMPLETED
- Phase
- PHASE1
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
- Status
- COMPLETED
- Phase
- PHASE1
Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
- Status
- COMPLETED
- Phase
- PHASE3
Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy
- Status
- WITHDRAWN
- Phase
- PHASE2
Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin
- Status
- COMPLETED
- Phase
- PHASE2
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
- Status
- COMPLETED
- Phase
- N/A
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
- Status
- COMPLETED
- Phase
- PHASE3
Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects
- Status
- TERMINATED
- Phase
- PHASE1
Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours
- Status
- COMPLETED
- Phase
- PHASE1
Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy
- Status
- COMPLETED
- Phase
- N/A